The stock of Sage Therapeutics Inc (SAGE) is currently priced at $8.76. In the last session, the stock climbed significantly, topping out at $12.0 after opening at $8.76. The day’s lowest price was $6.0 before the stock closed at $8.97.
The market performance of Sage Therapeutics Inc’s stock has been harmonious in recent times.
52-week price history of SAGE Stock
A stock’s 52-week high and low prices can reveal much about its current status and future trajectory. Sage Therapeutics Inc’s current trading price is -34.97% away from its 52-week high, while its distance from the 52-week low is 89.61%. The stock’s price range during this period has spanned from $4.62 to $13.47. In the Healthcare sector, the Sage Therapeutics Inc’s shares surpassed a trading volume of approximately 6.13 million for the day, which was noticeably higher compared to the average daily volume of 9.1.7 million over the past three months.
Market Capitalization and Financial Performance: An In-Depth Look
Sage Therapeutics Inc (SAGE) has experienced a quarterly rise of 17.74% in its revenues when compared to the same period in the previous year. Presently, the company has a total market capitalization of 548.57M and boasts a workforce of 353 employees.
A Closer Look at Analysts’ Ratings for Sage Therapeutics Inc
As of right now, 0 analyst is rating Sage Therapeutics Inc as a BUY, 0 of the polled analysts branded the stock as an OVERWEIGHT, 15 analysts are recommending to HOLD this stock, 0 of them gave the stock UNDERWEIGHT rating, and 0 analyst is rating the stock as SELL.
Making Sense of Trading Volume and Moving Average Data
Based on Barchart.com data, the company’s moving average over the 100-day period was 7.73, with a change in price of +1.59. Similarly, Sage Therapeutics Inc recorded 1,582,993 in trading volume during the last 100 days, posting a change of +22.18%.
Examining SAGE’s Debt-to-Equity Ratio: What You Need to Know
The debt-to-equity (D/E) ratio is a crucial measure that sheds light on a company’s financial health and market standing. It is determined by dividing a company’s overall liabilities by its shareholders’ equity, showing the extent of a company’s debt usage in financing its assets compared to the shareholders’ equity. At the time of writing, the total D/E ratio for SAGE stands at 0.03. Similarly, the long-term debt-to-equity ratio is also 0.02.
SAGE Stock Stochastic Average
Today’s raw stochastic average for Sage Therapeutics Inc over the last 50 days is 80.07%.This indicates a increase from the raw stochastic average of the past 20 days, which was 1.64%. Moreover, the company’s Stochastic %K and %D values for the last 20 days were 8.67% and 18.34%, respectively.
SAGE Stock Price Performance Analysis
The stock price performance this year has been a mixed bag, which means people have different opinions about whether it’s been good or bad. Some may see it as optimistic, while others may view it as pessimistic. The metric has seen a significant loss of -28.02% since the start of this calendar year. Looking back over the last six months, we can see a weaker performance of 23.73%. Over the past 30 days, the price of SAGE has leaped by -5.81%. And in the last five days, it has fallen by -4.47%.
